Drugs / DTRMWXHS-12
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT03836768 | Jan 2019 → Nov 2021 | mantle cell lymphoma | Zhejiang DTRM Biopharma | Completed | No outcome recorded |
| Phase 1 | NCT02900716 | Sep 2016 → Nov 2020 | B-cell chronic lymphocytic leukemia | Zhejiang DTRM Biopharma | Completed | No outcome recorded |
| Phase 1 | NCT02891590 | Sep 2016 → Feb 2019 | B-cell chronic lymphocytic leukemia | Zhejiang DTRM Biopharma | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04305444 | Apr 2020 → Dec 2024 | B-cell chronic lymphocytic leukemia, Richter transformation, diffuse large B-cell lymphoma, follicular lymphoma | Zhejiang DTRM Biopharma | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DTRMWXHS-12 | “Phase Ia explored escalating doses of a monotherapy of a novel Bruton's Tyrosine Kinase (BTK) inhibitor, DTRMWXHS-12.” NCT04305444 ↗ |
| Action | Inhibit | “BTK Inhibitor DTRMWXHS-12” NCT02891590 ↗ |
| Route | Oral | “multiple dose oral administration of DTRMWXHS-12 capsule” NCT02891590 ↗ |
| Target | BTK | “BTK Inhibitor DTRMWXHS-12” NCT02891590 ↗ |